MCID: LCL006
MIFTS: 59

Localized Scleroderma malady

Categories: Genetic diseases, Rare diseases, Skin diseases, Immune diseases, Neuronal diseases, Nephrological diseases, Respiratory diseases, Bone diseases

Aliases & Classifications for Localized Scleroderma

About this section
Sources:
11Disease Ontology, 13DISEASES, 29ICD10, 30ICD10 via Orphanet, 31ICD9CM, 38MeSH, 39MESH via Orphanet, 44NCIt, 47NIH Rare Diseases, 49Novoseek, 53Orphanet, 61SNOMED-CT, 67UMLS, 68UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Localized Scleroderma:

Name: Localized Scleroderma 11 47 53 13 67
Morphea 11 47 49 67
Localized Fibrosing Scleroderma 47 53
Scleroderma, Circumscribed or Localized 11
Unspecified Circumscribed Scleroderma 11
 
Circumscribed Scleroderma Nos 11
Circumscribed Scleroderma 11
Scleroderma, Localized 47
Localised Morphoea 11
Localized Morphea 11

Characteristics:

Orphanet epidemiological data:

53
localized scleroderma:
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: normal life expectancy

Classifications:

Orphanet: 53 
Rare skin diseases


External Ids:

Disease Ontology11 DOID:8472
ICD1029 L94.0
ICD9CM31 701.0
MeSH38 D012594
NCIt44 C72069
Orphanet53 ORPHA90289
UMLS via Orphanet68 C0036420
ICD10 via Orphanet30 L94.0
MESH via Orphanet39 D012594

Summaries for Localized Scleroderma

About this section
Wikipedia:70 Morphea, also called localized scleroderma or circumscribed scleroderma, is a form of scleroderma that... more...

MalaCards based summary: Localized Scleroderma, also known as morphea, is related to skin disease and hypothyroidism, and has symptoms including dry skin, hypopigmented skin patches and skeletal muscle atrophy. An important gene associated with Localized Scleroderma is MMP1 (Matrix Metallopeptidase 1), and among its related pathways are Syndecan-1-mediated signaling events and IL-9 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types. Affiliated tissues include skin, lung and bone, and related mouse phenotypes are craniofacial and neoplasm.

Related Diseases for Localized Scleroderma

About this section

Diseases in the Systemic Scleroderma family:

Scleroderma, Familial Progressive localized scleroderma

Diseases related to Localized Scleroderma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 188)
idRelated DiseaseScoreTop Affiliating Genes
1skin disease29.8IL6, TNF
2hypothyroidism29.6IL6, TNF
3gingivitis29.4IL6, TGFB1, TNF
4rheumatoid arthritis28.7IL6, MMP1, MMP13, TGFB1, TNF
5linear scleroderma11.2
6hemifacial atrophy, progressive11.1
7systemic scleroderma11.0
8atrophoderma of pierini and pasini10.9
9fibromatosis, gingival, 110.5MMP1, TGFB1
10lymphogranuloma venereum10.5CTGF, TGFB1
11congenital methemoglobinemia10.5IL6, TGFB1
12melorheostosis10.5IL6, MMP1
13vibrio vulnificus infection10.5IL6, TGFB1
14strawberry gallbladder10.5BMP6, TGFB1
15stomatitis10.5CTGF, TGFB1
16acromicric dysplasia10.4CTGF, TGFB1
17parsonage turner syndrome10.4TGFB1, TNF
18myopathy-growth delay-intellectual disability-hypospadias syndrome10.4TGFB1, TNF
19pneumoconiosis due to talc10.4TGFB1, TNF
20osteogenesis imperfecta, type x10.4IL6, MMP1
21panner disease10.4IL6, TNF
22aortic arch interruption10.3IL6, TNF
23cutaneous leishmaniasis10.3IL6, TNF
24addison's disease10.3TGFB1, TNF
25naegeli-franceschetti-jadassohn syndrome/dermatopathia pigmentosa reticularis10.3BMP6, DCN, TGFB1
26beare-stevenson cutis gyrata syndrome10.3BMP6, DCN, TGFB1
27maligant granulosa cell tumor of ovary10.3IL6, TNF
28hemometra10.3IL6, TNF
29tricho odonto onycho dermal syndrome10.3IL6, TNF
30ectopia lentis, familial10.3BMP6, DCN, TGFB1
31salt and pepper syndrome10.3CTGF, MMP1, TGFB1
32epstein-barr virus hepatitis10.3IL6, TNF
33abdominal chemodectomas with cutaneous angiolipomas10.3IL6, TNF
34pauciarticular onset juvenile idiopathic arthritis10.3DCN, MMP1
35antigen-peptide-transporter 2 deficiency10.3IL6, TNF
36hypohidrosis10.3BMP6, CTGF, TGFB1
37autoimmune polyendocrine syndrome10.3IL6, TNF
38splenic manifestation of prolymphocytic leukemia10.3IL6, TNF
39head and neck carcinoma10.2SMAD3, TGFB1
40pasteurellosis10.2IL6, TNF
41scarlet fever10.2IL6, TNF
42lymphocytic colitis10.2IL6, TNF
43keratomalacia10.2CTGF, TNF
44mastoiditis10.2IL6, MMP1, MMP13
45non-secretory myeloma10.2IL6, TNF
46rhizomelic pseudopolyarthritis10.2SELE, TNF
47pulmonary systemic sclerosis10.2BMP6, TGFB1, TNF
48gonococcal synovitis10.2SELE, TNF
49potato nose10.2BMP6, TNF
50atypical depressive disorder10.1IL6, TNF

Comorbidity relations with Localized Scleroderma via Phenotypic Disease Network (PDN):


Systemic SclerodermaVulva Cancer

Graphical network of the top 20 diseases related to Localized Scleroderma:



Diseases related to localized scleroderma

Symptoms for Localized Scleroderma

About this section

Human phenotypes related to Localized Scleroderma:

 63 53 (show all 20)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dry skin63 hallmark (90%) HP:0000958
2 hypopigmented skin patches63 hallmark (90%) HP:0001053
3 skeletal muscle atrophy63 53 typical (50%) Frequent (79-30%) HP:0003202
4 camptodactyly of toe63 occasional (7.5%) HP:0001836
5 lower limb asymmetry63 occasional (7.5%) HP:0100559
6 hyperpigmentation of the skin53 Very frequent (99-80%)
7 hypopigmentation of the skin53 Very frequent (99-80%)
8 cigarette-paper scars53 Very frequent (99-80%)
9 split hand53 Occasional (29-5%)
10 arthralgia53 Occasional (29-5%)
11 dermal atrophy53 Very frequent (99-80%)
12 scarring alopecia of scalp53 Occasional (29-5%)
13 flexion contracture of toe53 Occasional (29-5%)
14 stiff skin53 Very frequent (99-80%)
15 hemiatrophy53 Occasional (29-5%)
16 hemiatrophy of lower limb53 Occasional (29-5%)
17 hemiatrophy of upper limb53 Occasional (29-5%)
18 lipoatrophy53 Occasional (29-5%)
19 flexion contracture53 Occasional (29-5%)
20 myalgia53 Occasional (29-5%)

UMLS symptoms related to Localized Scleroderma:


exanthema, pruritus, skin manifestations

Drugs & Therapeutics for Localized Scleroderma

About this section

Drugs for Localized Scleroderma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 134)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1VaccinesPhase 46428
2
Cyclophosphamideapproved, investigationalPhase 3, Phase 2, Phase 1282950-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
3
Bosentanapproved, investigationalPhase 2, Phase 3103147536-97-8104865
Synonyms:
-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide
147536-97-8
174227-18-0
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide
4-t-butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide
AC-148
AC1L2XN2
Actelion
Bosentan
Bosentan (INN)
Bosentan [USAN:INN:BAN]
Bosentan hydrate
C27H29N5O6S
CHEBI:51450
CHEMBL957
CID104865
D07538
DB00559
 
EN002863
HMS2090N14
I06-1873
KS-5062
L001086
LS-31532
MolPort-003-845-300
NCGC00167440-01
PDSP1_001731
PDSP2_001714
Ro 47-0203
Ro 47-0203/039
Ro-47-0203
Ro-47-0203/029
Ro-47-0203/039
TL8001039
Tracleer
UNII-XUL93R30K2
bosentan
bosentanum
bosentán
p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide
p-tert-Butyl-N-[6-(2-hydroxyethoxy)
4
LenograstimapprovedPhase 31202135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
5
AcetylcholineapprovedPhase 377651-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
O-Acetylcholine
acetylcholine chloride
6
Lidocaineapproved, vet_approvedPhase 2, Phase 31226137-58-63676
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
AKOS001026768
ARONIS23855
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
Alphacaine
Anestacon
Anestacon Jelly
BIDD:GT0342
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
C07073
C14H22N2O
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
CPD000058189
Cappicaine
Cito optadren
Cuivasil
D00358
DB00281
Dalcaine
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L-Caine
L0156
L1026_SIGMA
L7757_SIGMA
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
LIDOPEN
LQZ
 
LS-805
Lanabiotic
Leostesin
Lida-Mantle
Lidocaina
Lidocaina [INN-Spanish]
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine Carbonate
Lidocaine Hydrocarbonate
Lidocaine Monohydrochloride
Lidocaine [USAN:INN:JAN]
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
Lignocaine
Lignocainum
Lingocaine
Lopac-L-5647
Lopac0_000669
MLS000069724
MLS000758263
MLS001074177
Maricaine
Maybridge1_002571
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
NINDS_000174
NSC 40030
NSC40030
Norwood Sunburn Spray
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
SPBio_001525
SPBio_002100
STK552033
Solarcaine
Solarcaine aloe extra burn relief cream
Solcain
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
Spectrum_001118
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-MPF
Xylocaine-MPF with Glucose
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
alpha-Diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-dimethylacetanilide
lidocaine
nchembio.65-comp16
α-diethylamino-2,6-dimethylacetanilide
7
Imiquimodapproved, investigationalPhase 313899011-02-657469
Synonyms:
1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine
1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine
1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine
1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine
1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
3M Brand of Imiquimod
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline
99011-02-6
AC-529
AC1L1N2I
AC1Q4YO9
Aldara
Aldara (TN)
Aldara, Imiquimod
BB_SC-2107
BIDD:GT0859
Beselna
C056493
CHEBI:36704
CHEMBL1282
CID57469
D02500
DB00724
DZ-2636
FT-0080222
HMS2090M14
 
I06-0624
I06-2289
I0747
I5159_SIGMA
IMIQUIMOD
Imiquimod
Imiquimod (JAN/USAN/INN)
Imiquimod [USAN:INN]
Imiquimod acetate
Imiquimodum
LS-178395
MLS000083577
MTD-39
MolPort-002-507-845
NCGC00070736-02
NSC369100
R 837
R-837
S 26308
S-26308
S1211_Selleck
SMR000048307
STK583860
TL8006059
TMX-101
UNII-P1QW714R7M
ZINC19632912
Zartra
Zyclara
imiquimod
8
Tadalafilapproved, investigationalPhase 3149171596-29-5110635
Synonyms:
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
171596-29-5
1xoz
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
AC1L380B
ADCIRCA
Acdirca
Adcirca
C429886
CHEBI:41488
CHEMBL779
CID110635
CPD000466321
Cialis
Cialis (TN)
Cialis, GF 196960, IC 351, ICOS 351, Tadalafil
D02008
DB00820
FT-0080116
GF 196960
GF-196960
 
HMS2051N17
HSDB 7303
IC 351
IC-351
ICOS 351
Ic351
KS-1117
LS-186558
LS-187015
LS-187770
Lilly brand of tadalafil
MLS000759426
MLS001165782
MLS001195644
MLS001424132
MolPort-002-885-864
S1512_Selleck
SAM001246586
SMR000466321
Tadalafil
Tadalafil (JAN/USAN/INN)
Tadalafil [USAN]
Tadanafil
UNII-742SXX0ICT
ZINC03993855
9
Domperidoneapproved, investigational, vet_approvedPhase 34857808-66-93151
Synonyms:
1-(3-(4-(5-chloro-2-oxo-2,3-Dihydrobenzo[D]imidazol-1-yl)piperidin-1-yl)propyl)-1H-benzo[D]imidazol-2(3H)-one
4-(5-Chloro-2-oxo-1-benzimidazolinyl)-1-[3-(2-oxobenzimidazolinyl)propyl]piperidine
5-24-02-00402 (Beilstein Handbook Reference)
5-Chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone
5-Chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]- 1,3-dihydro-2H-benzimidazol-2-one
5-Chloro-1-[1-[3-(2-oxo-1-benzimidazolinyl)propyl]-4-piperidyl]-2-benzimidazolinone
5-chloro-1-(1-(3-(2-oxo-1-Benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone
5-chloro-1-(1-(3-(2-oxo-2,3-Dihydrobenzo[D]imidazol-1-yl)propyl)piperidin-4-yl)-1H-benzo[D]imidazol-2(3H)-one
5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one
5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one
5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one
57808-66-9
6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one
83898-65-1 (maleate (1:1))
99497-03-7 (maleate)
AB00052423
AC-2037
AC1L1FAB
BPBio1_000620
BPBio1_001185
BRD-K38305202-001-02-6
BRN 0903774
BSPBio_002350
Biomol-NT_000022
C22H24ClN5O2
CHEBI:31515
CHEBI:464745
CHEMBL219916
CID3151
D-122
D01745
D122_SIGMA
DB01184
DivK1c_006921
Domperidon
Domperidona
Domperidona [INN-Spanish]
Domperidone (JAN/USAN/INN)
Domperidone [USAN:BAN:INN:JAN]
Domperidonum
Domperidonum [INN-Latin]
EINECS 260-968-7
EU-0100427
HMS1922N04
HMS2089C14
HMS2093N22
HS-0067
I01-0054
I14-14161
KBio1_001865
KBio2_000871
 
KBio2_003439
KBio2_006007
KBioGR_000354
KBioSS_000871
KW 5338
KW-5338
L000230
LS-33301
Lopac-D-122
Lopac0_000427
MLS000859942
MLS001306482
MLS002222324
Motilium
Motilium (TN)
NCGC00014670
NCGC00014670-05
NCGC00014670-13
NCGC00015306-01
NCGC00021472-02
NCGC00021472-03
NCGC00021472-04
NCGC00021472-05
NCGC00021472-06
NCGC00021472-07
NCGC00021472-08
NCGC00097773-01
NCI299589
NCI60_002512
NCIStruc1_001686
NCIStruc2_001819
NSC-299589
NSC299589
Nauzelin
Prestwick0_000461
Prestwick1_000461
Prestwick2_000461
Prestwick3_000461
Prestwick_794
R 33,812
R-33,812
R-33812
S2461_Selleck
SMR000326802
SPBio_002501
SPECTRUM2300212
STK622843
SpecPlus_000825
Spectrum4_000087
Spectrum_000391
UNII-5587267Z69
domperidone
10
Omeprazoleapproved, investigational, vet_approvedPhase 333773590-58-64594
Synonyms:
( -)-Omeprazole
(-)-Omeprazole
(S)-(-)-Omeprazole
(S)-Omeprazole
119141-89-8
131959-78-9
172964-80-6
2,3,5-Trimethylpyridine/Omeprazole
2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole
2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole
5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
73590-58-6
AC-401
AC1L1IIJ
AGI-010
AKOS005066653
AULCER
Antra
Antra MUPS
Audazol
Aulcer
Axagon
BIDD:GT0189
BPBio1_000425
BRD-A55962179-001-04-9
BSPBio_000385
Belmazol
Bio-0888
C07324
CAS-73590-58-6
CCRIS 7099
CHEBI:519601
CHEBI:7772
CHEMBL1503
CID4594
CPD000058847
Ceprandal
D00455
DB00338
DB00736
DM-3458
Danlox
Demeprazol
Desec
Dizprazol
Dudencer
Elgam
Emeproton
Emilok
Epirazole
Erbolin
Esomeprazole
Esomperazole
Esopral
Exter
Gasec
Gastrimut
Gastroloc
Gibancer
H 168-68
H 168/68
H-168/68
H168/68
HMS1528I05
HMS1569D07
HMS2052G17
HMS2090E16
HMS2090F11
HSDB 3575
I06-0705
IDI1_032523
Indurgan
Inhibitron
Inhipump
LS-7629
Lensor
Logastric
Lomac
Losec
Losec, Omesec, Prilosec, Zegerid, Omeprazole
Lucen
MLS000069373
MLS001076112
MLS001424148
Maybridge4_002645
Mepral
Miol
Miracid
MolPort-003-666-741
MolPort-003-807-515
MolPort-003-849-702
Mopral
Morecon
NCGC00016925-01
 
NCGC00016925-02
NCGC00021522-03
NCGC00021522-04
NCGC00021522-05
Nexiam
Nexium
Nexium IV
Nilsec
Nopramin
Nuclosina
O0359
O104_SIGMA
OMEP
OMP
OMZ
Ocid
Olexin
Olit
Omapren
Omebeta
Omebeta 20
Omed
Omegast
Omepradex
Omepral
Omeprazol
Omeprazol [INN-Spanish]
Omeprazole
Omeprazole (JAN/USP/INN)
Omeprazole Pellets
Omeprazole [USAN:INN:BAN:JAN]
Omeprazole delayed-release
Omeprazole magnesium
Omeprazolum
Omeprazolum [INN-Latin]
Omeprazon
Omeprazone
Omeprol
Omesek
Omez
Omezol
Omezolan
Omid
Omisec
Omizac
Ompanyt
Ortanol
Osiren
Ozoken
Paprazol
Parizac
Pepticum
Pepticus
Peptilcer
Prazentol
Prazidec
Prazolit
Prestwick0_000493
Prestwick1_000493
Prestwick2_000493
Prestwick3_000493
Prestwick_808
Prilosec
Prilosec (TN)
Prilosec OTC
Procelac
Proclor
Prysma
Ramezol
Regulacid
Result
S1389_Selleck
SAM001246900
SAN-15
SMR000058847
SPBio_002306
STK623746
Sanamidol
Secrepina
TL8005099
Tedec Ulceral
UNII-KG60484QX9
UPCMLD-DP075
UPCMLD-DP075:001
Ulceral
Ulcesep
Ulcometion
Ulcozol
Ulcsep
Ulsen
Ultop
Ulzol
Victrix
Zefxon
Zegerid
Zepral
Zimor
Zoltum
esomeprazol
omeprazole
11
DopamineapprovedPhase 3375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
12
Glucosamineapproved, NutraceuticalPhase 2, Phase 31823416-24-8439213
Synonyms:
(+)-2-amino-2-deoxy-D-glucopyranose
(2R,3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol
(2S,5R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol
(3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol
14257-69-3
2-Amino-2-deoxy-D-Glucose
2-Amino-2-deoxy-D-glucopyranose
2-Amino-2-deoxy-D-glucose
2-Amino-2-deoxy-beta-D-glucopyranose
2-Amino-2-deoxyglucose
2-Aminoglucose
2-Deoxy-2-amino-D-glucose
2-Deoxy-2-aminoglucose
2-amino-2-deoxy-D-glucopyranose
2-amino-2-deoxyglucose
2351-15-7
28905-10-4
2B4D44B2-D5AC-4DA4-9BE6-A4AE9574E4A6
3416-24-8
4-04-00-02017 (Beilstein Handbook Reference)
58-87-7
58267-75-7
6490-70-6
880765-44-6
90-77-7
911653-84-4
AC1L2D1C
AC1L96WB
AC1L9B8P
AC1Q4UBH
BRN 1724602
BSPBio_002086
C00329
C08349
CHEBI:28393
CHEBI:47977
CHEMBL234432
CID18897
CID439213
CID441477
CPD0-1193
Chitosamine
Cosamin
D-(+)-Glucosamine
 
D-Glucosamine
D-glucosamine
D04334
DB01296
DivK1c_000261
EINECS 222-311-2
GCS
Glucosamina
Glucosamina [INN-Spanish]
Glucosamine (USAN/INN)
Glucosamine [USAN:INN]
Glucosaminum
Glucosaminum [INN-Latin]
HMS500N03
HSDB 7469
IDI1_000261
InChI=1/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4-,5-,6-/m1/s1
KBio1_000261
KBio2_001311
KBio2_003879
KBio2_006447
KBio3_001306
KBioGR_000970
KBioSS_001311
LS-71671
MolPort-002-507-091
MolPort-003-944-937
NCGC00164421-01
NCGC00178826-01
NINDS_000261
SPBio_000477
STK801823
Spectrum2_000519
Spectrum3_000443
Spectrum4_000565
Spectrum5_000756
Spectrum_000831
Viartril-S
beta-D-Glucosamine
bmse000247
chitosamine
glucosamine
nchembio.189-comp4
nchembio.2007.41-comp7
nchembio.412-comp5
partially N-deacetylated poly-beta-1,6-N-acetyl-D-glucosamine
13Antirheumatic AgentsPhase 3, Phase 2, Phase 110627
14Immunosuppressive AgentsPhase 3, Phase 2, Phase 112770
15Antineoplastic Agents, AlkylatingPhase 3, Phase 2, Phase 14474
16Alkylating AgentsPhase 3, Phase 2, Phase 14694
17Antihypertensive AgentsPhase 2, Phase 34095
18onabotulinumtoxinAPhase 3626
19abobotulinumtoxinAPhase 3626
20Calcium, DietaryPhase 3, Phase 2, Phase 15525
21Sodium Channel BlockersPhase 2, Phase 31515
22Chelating AgentsPhase 3, Phase 21365
23Botulinum ToxinsPhase 3669
24Endothelin Receptor AntagonistsPhase 2, Phase 3215
25Cholinergic AgentsPhase 33846
26Neurotransmitter AgentsPhase 317734
27Pharmaceutical SolutionsPhase 2, Phase 37793
28Neuromuscular AgentsPhase 31129
29Insulin, Globin ZincPhase 34523
30incobotulinumtoxinAPhase 3635
31insulinPhase 34524
32Botulinum Toxins, Type APhase 3630
33Hypolipidemic AgentsPhase 2, Phase 32721
34Sildenafil CitratePhase 3323171599-83-0
35Peripheral Nervous System AgentsPhase 2, Phase 322776
36AnestheticsPhase 2, Phase 39001
37Phosphodiesterase InhibitorsPhase 31254
38Phosphodiesterase 5 InhibitorsPhase 3571
39Adjuvants, ImmunologicPhase 32484
40Interferon InducersPhase 3285
41interferonsPhase 3, Phase 12137
42Anesthetics, LocalPhase 2, Phase 33272
43Vasodilator AgentsPhase 3, Phase 23438
44Anti-Arrhythmia AgentsPhase 2, Phase 32969
45Hypoglycemic AgentsPhase 2, Phase 35733
46Lipid Regulating AgentsPhase 2, Phase 32702
47Fibrinolytic AgentsPhase 2, Phase 32317
48Glucuronyl glucosamine glycan sulfatePhase 2, Phase 3132
49AnticoagulantsPhase 2, Phase 3, Phase 12516
50Diuretics, Potassium SparingPhase 2, Phase 31827

Interventional clinical trials:

(show top 50)    (show all 75)
idNameStatusNCT IDPhase
1Influenza Vaccination in Patients With SclerodermaUnknown statusNCT01002508Phase 4
2Imiquimod in Children With Plaque MorpheaCompletedNCT00147771Phase 3
3Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDYCompletedNCT01295736Phase 3
4High Dose Cyclophosphamide for Treatment of SclerodermaCompletedNCT00501995Phase 3
5Effectiveness and Safety of Lidocaine for SclerodermaCompletedNCT00740285Phase 2, Phase 3
6A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in SclerodermaCompletedNCT01117298Phase 3
7Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's SyndromeCompletedNCT02165111Phase 3
8Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With SclerodermaCompletedNCT00070590Phase 2, Phase 3
9Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic SclerosisCompletedNCT01347008Phase 3
10Scleroderma Lung DiseaseCompletedNCT00004563Phase 3
11Gastroesophageal Reflux Treatment in SclerodermaRecruitingNCT01878526Phase 3
12Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label StudyWithdrawnNCT00230373Phase 3
13A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and EfficacyUnknown statusNCT00936546Phase 2
14IL1-TRAP, Rilonacept, in Systemic SclerosisUnknown statusNCT01538719Phase 1, Phase 2
15Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)Unknown statusNCT00883129Phase 2
16Efficacy and Safety of Imatinib in SclerodermaCompletedNCT00479934Phase 2
17Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal MatrixCompletedNCT00129428Phase 1, Phase 2
18Effect of Bosentan in Scleroderma Renal CrisisCompletedNCT01241383Phase 2
19Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil DiethanolamineCompletedNCT00775463Phase 2
20Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary FibrosisCompletedNCT00764309Phase 1, Phase 2
21Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic SclerodermaCompletedNCT00278525Phase 2
22Oral Type I Collagen for Relieving SclerodermaCompletedNCT00005675Phase 2
23A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)CompletedNCT00442611Phase 1, Phase 2
24Psychological Treatments for SclerodermaCompletedNCT00007267Phase 2
25Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse SclerodermaRecruitingNCT02370784Phase 2
26Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem CellsRecruitingNCT02213705Phase 1, Phase 2
27Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital UlcersRecruitingNCT02801305Phase 2
28Riociguat in Scleroderma Associated Digital UlcersRecruitingNCT02915835Phase 2
29Zibotentan Better Renal Scleroderma Outcome StudyRecruitingNCT02047708Phase 2
30Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial HypertensionRecruitingNCT02682511Phase 2
31Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung DiseaseActive, not recruitingNCT01559129Phase 2
32Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse SclerodermaTerminatedNCT01545427Phase 2
33Placebo Controlled Trial of Bosentan in Scleroderma PatientsTerminatedNCT00377455Phase 2
34A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis CutisWithdrawnNCT01918904Phase 2
35A Study of the Safety and Tolerability of MEDI-551 in SclerodermaCompletedNCT00946699Phase 1
36A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With SclerodermaCompletedNCT00930683Phase 1
37Novel Rehabilitation Strategies to Improve Arm Function in Patients With SclerodermaRecruitingNCT02837549Phase 1
38Safety & Suitability of Dabigatran to Inhibit Thrombin in SclerodermaRecruitingNCT02426229Phase 1
39Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma PatientsTerminatedNCT00040651Phase 1
40Comparative Effectiveness Trial in the Treatment of Pediatric Plaque MorpheaWithdrawnNCT02680717Phase 1
41Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized SclerodermaUnknown statusNCT02002897
42Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for MorpheaUnknown statusNCT01799174
43Empirical Comparative Study of Variation Blood Level Antibody Vitamin D at Scleroderma (SSc) Patients Compared Healthy PeoplesUnknown statusNCT01553890
44Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.CompletedNCT00812188
45The CARRA RegistryCompletedNCT01697254
46UVA1 Light for Treatment of Scleroderma and Similar ConditionsCompletedNCT00476801
47Morbidity and Mortality Follow Up for the Scleroderma Lung StudyCompletedNCT01762449
48Finger Hardness Measure in SclerodermaCompletedNCT01111786
49Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung InvolvementCompletedNCT00333437
50Genesis of Scleroderma: Role of Environmental Factors in 100 Patients With Scleroderma and 300 ControlsCompletedNCT00213525

Search NIH Clinical Center for Localized Scleroderma

Genetic Tests for Localized Scleroderma

About this section

Anatomical Context for Localized Scleroderma

About this section

MalaCards organs/tissues related to Localized Scleroderma:

35
Skin, Lung, Bone, Endothelial, Bone marrow, Breast, Skeletal muscle

Animal Models for Localized Scleroderma or affiliated genes

About this section

MGI Mouse Phenotypes related to Localized Scleroderma:

40 (show all 11)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053829.4CTGF, DCN, SMAD3, TGFB1, TNF
2MP:00020069.0DCN, IL6, MMP1, SMAD3, TGFB1, TNF
3MP:00053819.0CTGF, DCN, IL6, SMAD3, TGFB1, TNF
4MP:00053888.6CTGF, DCN, IL6, SELE, TGFB1, TNF
5MP:00053858.1CTGF, IL6, MMP13, SELE, SMAD3, TGFB1
6MP:00053907.9BMP6, CTGF, DCN, IL6, MMP13, SMAD3
7MP:00053847.8CTGF, DCN, IL6, MMP13, SELE, SMAD3
8MP:00107717.7CTGF, DCN, IL6, MMP13, SELE, SMAD3
9MP:00053767.5CTGF, DCN, IL6, MMP1, MMP13, SELE
10MP:00053917.3CTGF, DCN, IL6, SELE, SMAD3, TGFB1
11MP:00053787.2BMP6, CTGF, DCN, IL6, MMP13, SELE

Publications for Localized Scleroderma

About this section

Articles related to Localized Scleroderma:

(show top 50)    (show all 366)
idTitleAuthorsYear
1
Lupus erythematosus and localized scleroderma coexistent at the same sites: a rare presentation of overlap syndrome of connective-tissue diseases. (27274545)
2016
2
Neurological abnormalities in localized scleroderma of the face and head: a case series study for evaluation of imaging findings and clinical course. (27700194)
2016
3
Measurement of transepidermal water loss in localized scleroderma. (26970329)
2016
4
Predictors of Longitudinal Quality of Life in Pediatric Localized Scleroderma. (27696700)
2016
5
Successful autologous hematopoietic stem cell transplantation for a patient with rapidly progressive localized scleroderma. (25923607)
2015
6
Pirfenidone gel in patients with localized scleroderma: a phase II study. (25533576)
2014
7
Parry Romberg syndrome with localized scleroderma: A case report. (25136439)
2014
8
Bath psoralen-UVA photochemotherapy for localized scleroderma: experience from a single institute. (24001380)
2013
9
Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis. (23557629)
2013
10
Coexistence of lichen sclerosus and morphea: a retrospective analysis of 472 patients with localized scleroderma from a German tertiary referral center. (22533994)
2012
11
Localized scleroderma associated with chronic hepatitis C. (23213578)
2012
12
Supernatants from culture of type I collagen-stimulated PBMC from patients with cutaneous systemic sclerosis versus localized scleroderma demonstrate suppression of MMP-1 by fibroblasts. (22367096)
2012
13
Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study. (22247357)
2012
14
Case of juvenile localized scleroderma with joint sclerosis and SjAPgren's syndrome in a child with precocious puberty. (21658114)
2011
15
Localized scleroderma: MR findings and clinical features. (21693661)
2011
16
Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. (21305525)
2011
17
Pathogenesis and treatment modalities of localized scleroderma. (21393982)
2010
18
Localized scleroderma in children: clinical, diagnostic and therapeutic aspects. (19503984)
2009
19
Choroidal sclerosis in localized scleroderma (morphea en plaque). (18223304)
2008
20
Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases. (17222220)
2007
21
Chronic venous insufficiency - a potential trigger for localized scleroderma. (16405619)
2006
22
Localized scleroderma is an autoimmune disorder. (15561734)
2005
23
Localized scleroderma: response to occlusive treatment with tacrolimus ointment. (15656828)
2005
24
Topical tacrolimus in the treatment of localized scleroderma. (14721783)
2003
25
Comparative biochemistry of human skin: glycosaminoglycans from different body sites in normal subjects and in patients with localized scleroderma. (12602961)
2003
26
Localized scleroderma in a 12-year-old girl presenting as gingival recession. A case report and literature review. (11806189)
2001
27
Serum levels of soluble interleukin 6 receptor and soluble gp130 are elevated in patients with localized scleroderma. (10955333)
2000
28
Effectiveness of topical calcitriol for localized scleroderma. (9918276)
1999
29
Low-dose UVA phototherapy for treatment of localized scleroderma. (9448200)
1998
30
Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma. (9091475)
1997
31
High-dose UVA1 radiation therapy for localized scleroderma. (9204059)
1997
32
Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma. (8736323)
1996
33
Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. (7763091)
1995
34
Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients. (8179352)
1994
35
Borrelia burgdorferi and localized scleroderma. (7954205)
1994
36
Localized scleroderma. (8076261)
1994
37
Prevalence and characteristics of anti-single-stranded DNA antibodies in localized scleroderma. Comparison with systemic lupus erythematosus. (1863075)
1991
38
20-MHz B-mode ultrasound in monitoring the course of localized scleroderma (morphea). (1812687)
1991
39
Localized scleroderma--response to 1,25-dihydroxyvitamin D3. (2225549)
1990
40
Localized scleroderma. (2702053)
1989
41
Localized scleroderma. (2671537)
1989
42
Frequency, levels, and significance of blood eosinophilia in systemic sclerosis, localized scleroderma, and eosinophilic fasciitis. (3668010)
1987
43
Localized scleroderma (morphea) and antibody to Borrelia burgdorferi. (3308981)
1987
44
Localized scleroderma evolving into systemic sclerosis. (4045867)
1985
45
Treatment of localized scleroderma and lichen sclerosus with etretinate. (6203311)
1984
46
Clinical appearance of skin lesions and disturbances of pigmentation in localized scleroderma. (6084919)
1984
47
Collagen specific amino acids in skin in localized scleroderma. (6203316)
1984
48
Presence of eosinophilia in progressive systemic sclerosis and localized scleroderma. (7332350)
1981
49
Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. (420706)
1979
50
Localized scleroderma and generalized sclerosis (five cases). (13781164)
1960

Variations for Localized Scleroderma

About this section

Expression for genes affiliated with Localized Scleroderma

About this section
Search GEO for disease gene expression data for Localized Scleroderma.

Pathways for genes affiliated with Localized Scleroderma

About this section

Pathways related to Localized Scleroderma according to GeneCards Suite gene sharing:

(show all 44)
idSuper pathwaysScoreTop Affiliating Genes
19.9MMP1, TGFB1
29.8IL6, TGFB1
39.7TGFB1, TNF
4
Show member pathways
9.6SMAD3, TGFB1
59.5DCN, IL6, MMP1
69.4IL6, MMP1, TNF
79.4IL6, TGFB1, TNF
89.4IL6, TGFB1, TNF
99.4IL6, TGFB1, TNF
109.4IL6, TGFB1, TNF
11
Show member pathways
9.4IL6, TGFB1, TNF
129.4IL6, TGFB1, TNF
139.4IL6, TGFB1, TNF
14
Show member pathways
9.3MMP1, MMP13, TNF
159.3CTGF, IL6, TNF
169.3IL6, SMAD3, TGFB1
17
Show member pathways
9.3IL6, SMAD3, TGFB1
18
Show member pathways
9.3IL6, SMAD3, TGFB1
19
Show member pathways
9.3IL6, SMAD3, TGFB1
209.3CTGF, SMAD3, TGFB1
219.2BMP6, MMP13, TGFB1
229.2SMAD3, TGFB1, TNF
23
Show member pathways
9.2DCN, MMP1, MMP13, TGFB1
249.2IL6, SMAD3, TNF
259.1BMP6, SMAD3, TGFB1
269.1BMP6, SMAD3, TGFB1
279.1IL6, MMP1, TGFB1, TNF
289.0IL6, MMP1, SELE
299.0IL6, MMP1, SMAD3, TGFB1
309.0BMP6, DCN, IL6, TGFB1
318.9BMP6, CTGF, IL6, TGFB1
328.9IL6, SELE, TNF
338.9IL6, SELE, TNF
348.8IL6, SMAD3, TGFB1, TNF
358.8IL6, SMAD3, TGFB1, TNF
368.7BMP6, CTGF, SMAD3, TGFB1
378.5IL6, MMP1, SMAD3, TGFB1, TNF
388.5IL6, SELE, TGFB1, TNF
39
Show member pathways
8.5BMP6, CTGF, IL6, TGFB1, TNF
40
Show member pathways
8.4BMP6, CTGF, IL6, SMAD3, TGFB1
418.0IL6, SELE, SMAD3, TGFB1, TNF
42
Show member pathways
7.9BMP6, CTGF, IL6, SMAD3, TGFB1, TNF
43
Show member pathways
7.9BMP6, CTGF, IL6, SMAD3, TGFB1, TNF
44
Show member pathways
7.7BMP6, CTGF, IL6, MMP1, MMP13, SMAD3

GO Terms for genes affiliated with Localized Scleroderma

About this section

Cellular components related to Localized Scleroderma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1Golgi lumenGO:00057969.6DCN, DEFB1, TGFB1
2proteinaceous extracellular matrixGO:00055788.9CTGF, DCN, MMP1, MMP13, TGFB1
3extracellular regionGO:00055767.1CTGF, DCN, DEFB1, IL6, MMP1, MMP13
4extracellular spaceGO:00056156.3BMP6, CTGF, DCN, DEFB1, IL6, MMP13

Biological processes related to Localized Scleroderma according to GeneCards Suite gene sharing:

(show all 46)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of mononuclear cell migrationGO:007167710.4TGFB1, TNF
2positive regulation of chemokine productionGO:003272210.4IL6, TNF
3epithelial cell proliferation involved in salivary gland morphogenesisGO:006066410.4IL6, TNF
4positive regulation of collagen biosynthetic processGO:003296710.3CTGF, TGFB1
5regulation of bindingGO:005109810.3SMAD3, TGFB1
6positive regulation of extracellular matrix assemblyGO:190120310.3SMAD3, TGFB1
7evasion or tolerance of host defenses by virusGO:001904910.3SMAD3, TGFB1
8positive regulation of protein complex assemblyGO:003133410.3TGFB1, TNF
9SMAD protein complex assemblyGO:000718310.3SMAD3, TGFB1
10regulation of striated muscle tissue developmentGO:001620210.3SMAD3, TGFB1
11negative regulation of lipid storageGO:001088810.2IL6, TNF
12lens fiber cell differentiationGO:007030610.2SMAD3, TGFB1
13cell-cell junction organizationGO:004521610.2SMAD3, TGFB1
14positive regulation of SMAD protein import into nucleusGO:006039110.2BMP6, TGFB1
15positive regulation of chondrocyte differentiationGO:003233210.1BMP6, SMAD3
16endoderm developmentGO:000749210.1SMAD3, TGFB1
17regulation of transforming growth factor beta receptor signaling pathwayGO:001701510.1SMAD3, TGFB1
18negative regulation of myoblast differentiationGO:004566210.0TGFB1, TNF
19acute inflammatory responseGO:000252610.0DEFB1, IL6
20extracellular matrix disassemblyGO:002261710.0DCN, MMP1, MMP13
21endochondral ossificationGO:00019589.9BMP6, MMP13
22response to woundingGO:00096119.9CTGF, IL6, TGFB1
23leukocyte tethering or rollingGO:00509019.9SELE, TNF
24positive regulation of protein kinase B signalingGO:00518979.9IL6, TGFB1, TNF
25response to organic cyclic compoundGO:00140709.9CTGF, IL6, TGFB1
26positive regulation of protein phosphorylationGO:00019349.8CTGF, TGFB1, TNF
27positive regulation of NF-kappaB transcription factor activityGO:00510929.8IL6, TGFB1, TNF
28extrinsic apoptotic signaling pathwayGO:00971919.8SMAD3, TGFB1, TNF
29response to mechanical stimulusGO:00096129.8DCN, IL6, MMP13
30positive regulation of bone mineralizationGO:00305019.8BMP6, SMAD3, TGFB1
31SMAD protein signal transductionGO:00603959.7BMP6, SMAD3, TGFB1
32response to glucocorticoidGO:00513849.7BMP6, IL6, TNF
33positive regulation of epithelial cell proliferationGO:00506799.7BMP6, IL6, TGFB1
34negative regulation of gene expressionGO:00106299.6CTGF, TGFB1, TNF
35positive regulation of peptidyl-serine phosphorylationGO:00331389.6IL6, TGFB1, TNF
36T cell activationGO:00421109.4IL6, SMAD3, TGFB1
37osteoblast differentiationGO:00016499.3BMP6, MMP13, SMAD3
38agingGO:00075689.3CTGF, DCN, IL6, TGFB1
39negative regulation of fat cell differentiationGO:00455999.2IL6, SMAD3, TGFB1, TNF
40wound healingGO:00420609.2DCN, IL6, SMAD3, TGFB1
41leukocyte migrationGO:00509009.2MMP1, SELE, TNF
42defense response to Gram-positive bacteriumGO:00508309.1DEFB1, IL6, TNF
43positive regulation of ERK1 and ERK2 cascadeGO:00703749.0CTGF, IL6, TNF
44positive regulation of gene expressionGO:00106288.5CTGF, IL6, SMAD3, TGFB1, TNF
45inflammatory responseGO:00069548.4BMP6, IL6, SELE, TGFB1, TNF
46positive regulation of transcription from RNA polymerase II promoterGO:00459448.0BMP6, DCN, IL6, SMAD3, TGFB1, TNF

Molecular functions related to Localized Scleroderma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1transforming growth factor beta receptor bindingGO:00051609.6BMP6, SMAD3, TGFB1
2cytokine activityGO:00051259.0BMP6, IL6, TGFB1, TNF
3collagen bindingGO:00055188.9DCN, MMP13, SMAD3
4growth factor activityGO:00080838.9BMP6, CTGF, IL6, TGFB1

Sources for Localized Scleroderma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet